Načítá se...
Ocrelizumab zur Behandlung der Multiplen Sklerose
Ocrelizumab is a monoclonal antibody directed against the differentiation antigen CD20, which leads to an effective long-term depletion of lymphocytes, in particular B cells. Recently published phase 3 studies confirmed that ocrelizumab is effective in the treatment of both relapsing multiple sclero...
Uloženo v:
| Vydáno v: | Nervenarzt |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Medizin
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7286209/ https://ncbi.nlm.nih.gov/pubmed/32524163 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00115-020-00937-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|